KR100512892B1 - 에이스저해제 질산염 - Google Patents

에이스저해제 질산염 Download PDF

Info

Publication number
KR100512892B1
KR100512892B1 KR10-1999-7011984A KR19997011984A KR100512892B1 KR 100512892 B1 KR100512892 B1 KR 100512892B1 KR 19997011984 A KR19997011984 A KR 19997011984A KR 100512892 B1 KR100512892 B1 KR 100512892B1
Authority
KR
South Korea
Prior art keywords
iii
formula
ring
residue
nitrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7011984A
Other languages
English (en)
Korean (ko)
Other versions
KR20010013958A (ko
Inventor
델솔다토피에로
Original Assignee
니콕스 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콕스 에스. 에이. filed Critical 니콕스 에스. 에이.
Publication of KR20010013958A publication Critical patent/KR20010013958A/ko
Application granted granted Critical
Publication of KR100512892B1 publication Critical patent/KR100512892B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
KR10-1999-7011984A 1997-06-27 1998-06-24 에이스저해제 질산염 Expired - Fee Related KR100512892B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI97A001523 1997-06-27
IT97MI001523A IT1292426B1 (it) 1997-06-27 1997-06-27 Sali nitrati di ace-inibitori
PCT/EP1998/003946 WO1999000361A1 (en) 1997-06-27 1998-06-24 Ace-inhibitor nitric salts

Publications (2)

Publication Number Publication Date
KR20010013958A KR20010013958A (ko) 2001-02-26
KR100512892B1 true KR100512892B1 (ko) 2005-09-07

Family

ID=11377450

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7011984A Expired - Fee Related KR100512892B1 (ko) 1997-06-27 1998-06-24 에이스저해제 질산염

Country Status (17)

Country Link
US (1) US6218417B1 (enExample)
EP (1) EP1019370B1 (enExample)
JP (1) JP2002506456A (enExample)
KR (1) KR100512892B1 (enExample)
CN (1) CN1205186C (enExample)
AT (1) ATE230393T1 (enExample)
AU (1) AU740411B2 (enExample)
BR (1) BR9810459A (enExample)
CA (1) CA2292794A1 (enExample)
DE (1) DE69810498T2 (enExample)
DK (1) DK1019370T3 (enExample)
ES (1) ES2190095T3 (enExample)
HU (1) HUP0003133A3 (enExample)
IL (1) IL132691A (enExample)
IT (1) IT1292426B1 (enExample)
RU (1) RU2194037C2 (enExample)
WO (1) WO1999000361A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
AU7365900A (en) 1999-09-08 2001-04-10 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
CA2386954C (en) 1999-10-29 2011-12-13 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
CA2446064A1 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP2042181A1 (en) * 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
SI21704A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia
JP2008506716A (ja) * 2004-07-16 2008-03-06 ニトロメッド インコーポレーティッド 心不全に関連する組成物および方法
JP2008510755A (ja) * 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
EP1679072B9 (en) * 2005-01-06 2009-09-02 IPCA Laboratories Limited Process for for synthesis of (2S,3aS,7aS)-1-(S)-alanyl-octahydro-1H-indole-2- carboxylic acid derivatives and use in the synthesis of perindopril
CA2606880A1 (en) * 2005-05-05 2006-11-16 Keryx Biopharmaceuticals, Inc. Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
AU2006253805A1 (en) * 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
JP2009514809A (ja) * 2005-10-18 2009-04-09 ニコックス エス エイ レニン阻害剤のニトロ誘導体
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
RU2425032C2 (ru) 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2007102127A2 (en) * 2006-03-08 2007-09-13 Actelion Pharmaceuticals Ltd New amines
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
JP4790871B2 (ja) * 2008-05-05 2011-10-12 メルク フロスト カナダ リミテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
DK0719253T3 (da) * 1993-09-17 2004-07-26 Pfizer 3-amino-5-carboxy-substituerede piperidiner og 3-amino-4-carboxy-substituerede pyrrolidiner som tachykininantagonister
CA2190087C (en) 1994-05-10 2005-08-02 Piero Del Soldato Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
AU4953796A (en) * 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
US5625083A (en) 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
CN1141771A (zh) * 1995-08-02 1997-02-05 贾力 巯-亚硝基化合物及其医学用途

Also Published As

Publication number Publication date
KR20010013958A (ko) 2001-02-26
BR9810459A (pt) 2006-10-03
ES2190095T3 (es) 2003-07-16
AU8730098A (en) 1999-01-19
CN1205186C (zh) 2005-06-08
ITMI971523A0 (enExample) 1997-06-27
DE69810498T2 (de) 2003-10-30
EP1019370A1 (en) 2000-07-19
JP2002506456A (ja) 2002-02-26
EP1019370B1 (en) 2003-01-02
ATE230393T1 (de) 2003-01-15
WO1999000361A1 (en) 1999-01-07
DK1019370T3 (da) 2003-05-05
CA2292794A1 (en) 1999-01-07
HUP0003133A2 (en) 2001-03-28
RU2194037C2 (ru) 2002-12-10
IT1292426B1 (it) 1999-02-08
HUP0003133A3 (en) 2002-10-28
DE69810498D1 (de) 2003-02-06
IL132691A (en) 2004-06-01
AU740411B2 (en) 2001-11-01
ITMI971523A1 (it) 1998-12-27
IL132691A0 (en) 2001-03-19
US6218417B1 (en) 2001-04-17
CN1260780A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
KR100512892B1 (ko) 에이스저해제 질산염
US4761399A (en) Dipeptide compounds having pharmaceutical activity and compositions containing them
US4668797A (en) Bicyclic aminoacids as intermediates and processes for their preparation
KR960003615B1 (ko) 메틸 α-5(4,5,6,7-테트라하이드로(3,2-C)티에노 피리딜)(2-클로로페닐)-아세테이트의 우선성 광학이성체, 그 제법 및 그의 약제학적 조성물
PT640617E (pt) Compostos azepino-(2,1-a)-isoquinolina substituidos
JPH0442400B2 (enExample)
EP0595878A1 (en) Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use
JPH05504775A (ja) トロンビンの阻害剤および基質
PT93245B (pt) Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem
EP0556482B1 (en) Propyl endopeptidase inhibitor
KR970008107B1 (ko) 항간질환성 조성물
EP0099709A2 (en) Amide derivatives
HU187808B (en) Process for the preparation of n-bracket-carboxy-alkyl-bracket-prolina containing tripeptides
EP0059966B1 (en) Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives
EP0175180A1 (en) Histargin-related compounds, a process for their preparation and their use as medicaments
JPH0745453B2 (ja) アシルアミノヒドロキシアルカノイルアミノおよびイミノ酸並びにエステル類
IE59185B1 (en) New derivatives of bicyclic amino acids, a process for their preparation, agents containing them and their use
EP0279750B1 (en) Aminoacid derivatives as antihypertensives
JP2860385B2 (ja) ビスべンジルイソキノリン誘導体
CA1193263A (en) 4-methylene-1-mercaptoacyl proline and pipecolic acid
KR100437670B1 (ko) (s)-이성체형태의인돌린설포닐우레아유도체
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤
SI8212567A8 (sl) Postopek za pripravo derivatov karboksialkildipeptidov

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080831

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080831

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000